1	A randomized trial shows dose-frequency and genotype may
2	determine the therapeutic efficacy of intranasal oxytocin
3	
4	Authors: Juan Kou ¹ , Yingying Zhang ¹ , Feng Zhou ¹ , Cornelia Sindermann ² , Christian
5	Montag ² , Benjamin Becker ¹ , Keith M Kendrick ^{1*}
6	
7	Affiliations:
8	¹ The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for
9	Neuroinformation, University of Electronic Science and Technology of China,
10	Chengdu 611731, China.
11	² Department of Molecular Psychology, Institute of Psychology and Education, Ulm
12	University, Ulm, Germany.
13	*Corresponding author: Keith M. Kendrick
14	Institute: The Clinical Hospital of Chengdu Brain Science, MOE Key Laboratory for
15	NeuroInformation
16	University: University of Electronic Science and Technology of China,
17	Street Name & Number: No. 2006, Xiyuan Ave, West Hi-tech Zone, Chengdu,
18	611731, China.
19	Tel: 86-28-83201358. Fax: 86-28-83201358.
20	E-mail: <u>kkendrick@uestc.edu.cn</u>
21	Word count: Abstract (212) Main part (5168)
22	

23 Abstract

24	Background. The neuropeptide oxytocin is proposed as a promising therapy for social
25	dysfunction by modulating amygdala-mediated social-emotional behavior. Although
26	clinical trials report some benefits of chronic treatment it is unclear whether efficacy
27	may be influenced by dose frequency or genotype.
28	Methods. In a randomized, double blind, placebo-controlled pharmaco-fMRI trial (150
29	male subjects) we investigated acute and different chronic (every day or on alternate
30	days for 5 days) intranasal oxytocin (24IU) effects and oxytocin receptor
31	genotype-mediated treatment sensitivity on amygdala responses to face emotions. We
32	also investigated similar effects on resting state functional connectivity between the
33	amygdala and prefrontal cortex.
34	Results. A single dose of oxytocin reduced amygdala responses to all face emotions
34 35	Results. A single dose of oxytocin reduced amygdala responses to all face emotions but for threatening (fear and anger) and happy faces this effect was abolished after daily
35	but for threatening (fear and anger) and happy faces this effect was abolished after daily
35 36	but for threatening (fear and anger) and happy faces this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime
35 36 37	but for threatening (fear and anger) and happy faces this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects
35 36 37 38	but for threatening (fear and anger) and happy faces this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects on reducing amygdala responses to face emotions only occurred in AA homozygotes of
35 36 37 38 39	but for threatening (fear and anger) and happy faces this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects on reducing amygdala responses to face emotions only occurred in AA homozygotes of rs53576 and A carriers of rs2254298. The effects of oxytocin on resting state functional
35 36 37 38 39 40	but for threatening (fear and anger) and happy faces this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects on reducing amygdala responses to face emotions only occurred in AA homozygotes of rs53576 and A carriers of rs2254298. The effects of oxytocin on resting state functional connectivity were not influenced by either dose-frequency or receptor genotype.

2

45 Introduction

46	Intranasal oxytocin (OT) has been proposed as novel treatment to attenuate social
47	dysfunctions and anxiety in autism spectrum disorder, social anxiety and
48	schizophrenia (Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Young and
49	Barrett, 2015) as well as an augmentative strategy to facilitate fear extinction
50	(Eckstein et al., 2015) and working memory performance (Zhao et al., 2018).
51	Following an initial landmark study in humans demonstrating that OT reduces
52	amygdala responses to threatening (fear and angry) face stimuli (Kirsch et al., 2005),
53	subsequent preclinical research has consistently reported that its effects on amygdala
54	function (attenuated fear reactivity and increased amygdala-prefrontal intrinsic
55	connectivity - Domes et al., 2007; Eckstein et al., 2017; Kendrick et al., 2017;
56	Meyer-Lindenberg et al., 2011; Quintana et al., 2016; Spengler et al., 2017; Sripada et
57	al., 2013; Wang et al., 2017) may represent its primary therapeutic-relevant neural
58	mechanism of action.
59	The proposed neural mechanisms of OT have been established using acute single
60	dose administration protocols, with a dose-response study demonstrating 24
61	International Units (IU) as optimal for reducing amygdala responses to fear stimuli
62	using conventional intranasal spray devices (Spengler et al., 2017). To date however,
63	no human studies have demonstrated whether chronic treatment protocols can produce
64	enhanced functional effects and initial clinical trials using chronic (twice daily)
65	administration over periods of a week or longer have reported inconsistent, or at best

66	modest therapeutic efficacy on social-emotional dysfunctions (Guastella et al., 2015;
67	Halverson et al., 2019; Jarskog et al., 2017; Kendrick et al., 2017; Watanabe et al.,
68	2015; Yamasue et al., 2018).
69	G-protein-coupled neuropeptide receptors typically exhibit internalization
70	following even a relatively short period of constant exposure to their target peptides
71	and cannot subsequently respond (desensitized) until they are recycled back the
72	surface of the cell membrane (Pierce et al., 2002; Lohse and Hofmann, 2015).
73	Growing evidence from both in vitro and animal studies suggest there may be
74	extensive internalization and subsequent desensitization of OT receptors (OXTR)
75	following repeated OT administration (Smith et al., 2006; Stoop, 2012). In terms of
76	neural OXTR receptors those in the amygdala may be particularly susceptible to
77	desensitization (Terenzi and Ingram, 2005) and this region critically mediates many of
78	the effects of intranasal OT on social cognition and anxiety (Kendrick et al., 2017).
79	Moreover, rodent models have reported that in contrast to single doses, chronic
80	administration of OT can actually produce social impairment (Bales et al., 2013; Du
81	et al., 2017; Huang et al., 2014) in the context of reduced receptor expression in the
82	amygdala and nucleus accumbens (Du et al., 2017). Furthermore, an initial study
83	reported that chronic versus single administration of OT results in divergent
84	neurochemical changes in both the rodent and human frontal cortex (Benner et al.,
85	2018), emphasizing high translational relevance of the preclinical animal models for
86	clinical trials employing chronic treatment protocols. Thus, empirically evaluated

optimal treatment protocols for chronic intranasal OT administration in humans areurgently needed to determine its therapeutic potential.

89	A further unresolved issue is that different OT receptor (OXTR) genotypes have
90	been associated with social behaviors and may influence sensitivity of behavioral and
91	neural responses to intranasal OT. In particular, OXTR polymorphisms rs53576 and
92	rs2254298 have been associated with autism (Cataldo et al., 2018), deficits in social
93	and emotional processing and anxiety (Jurek and Neumann, 2018; Parker et al., 2014;
94	Yang et al., 2017) and individual variations in behavioral and neural responses to
95	intranasal OT (Chen et al., 2015; Feng et al., 2015). Indeed, variants of rs2254298
96	may represent a trans-diagnostic biomarker for social dysfunctions (Br üne, 2012). It is
97	therefore imperative to establish whether OXTR polymorphisms could influence
98	sensitivity to effects of intranasal OT.
99	While single doses of OT can produce numerous functional effects, two of key
100	importance are attenuated amygdala responses to face emotions, particularly fear, and
100 101	importance are attenuated amygdala responses to face emotions, particularly fear, and increased resting state functional connectivity between the amygdala and prefrontal
101	increased resting state functional connectivity between the amygdala and prefrontal
101 102	increased resting state functional connectivity between the amygdala and prefrontal cortex (Domes et al., 2007; Eckstein et al., 2017; Kirsch et al., 2005; Koch et al., 2016;
101 102 103	increased resting state functional connectivity between the amygdala and prefrontal cortex (Domes et al., 2007; Eckstein et al., 2017; Kirsch et al., 2005; Koch et al., 2016; Quintana et al., 2016; Spengler et al., 2017; Sripada et al., 2013). While most task
101 102 103 104	increased resting state functional connectivity between the amygdala and prefrontal cortex (Domes et al., 2007; Eckstein et al., 2017; Kirsch et al., 2005; Koch et al., 2016; Quintana et al., 2016; Spengler et al., 2017; Sripada et al., 2013). While most task studies have focused on the effects of OT on amygdala responses to fear faces using a

108	attenuated anxiety in terms of reduced responses to social threat and enhanced
109	top-down control of emotion (Zhao et al., 2019), although effects of OT on the
110	amygdala may influence a range of social cognition domains (Kendrick et al., 2017;
111	Meyer-Lindenberg et al., 2011; Young and Barrett, 2015).
112	To help determine optimal treatment protocols for chronic intranasal OT
113	administration the current pre-registered double-blind, randomized between subject
114	placebo (PLC)-controlled pharmacological neuroimaging trial therefore aimed to
115	replicate previous findings for effects of a single dose of OT (24IU) on reduced
116	amygdala responses to fear or other face emotions (Domes et al., 2007; Kirsch et al.,
117	2005; Koch et al., 2016; Quintana et al., 2016; Spengler et al., 2017; Wang et al.,
118	2017) in a large sample at the whole brain level and on increasing resting-state
119	functional connectivity between the amygdala and prefrontal cortex (Eckstein et al.,
120	2017; Sripada et al., 2013). Next, the primary outcome of the trial was to establish
121	whether different repeat dosing protocols (daily, OT_5 group, or every other day, OT_3
122	group, for 5 days) modulate amygdala-centered neural and behavioral responses and
123	resting state functional connectivity. As a secondary outcome, we further aimed to
124	establish if effects of OT on primary outcome measures were influenced by OXTR
125	genotype, focusing on the rs53576 and rs2254298 polymorphisms most frequently
126	associated with social function and individual variations in intranasal OT sensitivity.

127 Material and Methods

128	The main study objectives were to investigate both the effects of acute (single dose)
129	and repeated doses (daily or every other day for 5 days) of 24IU OT versus PLC on
130	two primary outcomes: (1) amygdala and behavioral responses to face emotions
131	(particularly fear faces) and (2) resting state functional connectivity between the
132	amygdala and frontal cortex. We investigated modulatory influences of OXTR
133	rs53576 and rs2254298 polymorphisms on the sensitivity to intranasal OT as a
134	secondary outcome.

135 **Participants**

136	A total of 150, right-handed healthy adult male subjects were enrolled according to
137	common inclusion and exclusion criteria for human OT-administration studies (see
138	\mathbf{SI}). Given that methods for estimating power for whole brain task-based fMRI
139	analyses are limited (Poldrack et al., 2017), subject number was initially chosen on
140	the basis of recent large-scale studies investigating dose effects of OT (Spengler et al.,
141	2017 n = 111 males; Lieberz et al., 2019, 90 females). A priori power estimates for
142	behavioral analyses were calculated using Webpower (Zhang and Yuan, 2018) giving
143	a range of 60-80% power for ANOVA main and interaction effects and post-hoc tests.
144	For full details see SI. Calculating power for fMRI experiments is more problematic
145	and likely to be much lower, although since the amygdala was our only pre-registered
146	ROI of interest, and the majority of fMRI post-hoc analyses used a single amygdala
147	ROI, this avoids the problem of significantly reduced power when undirected whole
148	brain analyses are performed (see Cremers et al., 2017). The current chosen sample

149	size is also comparable to the previous largest fMRI studies investigating task-related
150	effects of OT (Spengler et al., 2017; Lieberz et al., 2019). Three subjects failed to
151	meet inclusion criteria (were currently taking medications) and 9 subjects were
152	excluded due to failure to complete the study or excessive head movement (see Fig.
153	S1). Subjects were randomly (computer-generated randomization) assigned to
154	repeated intranasal treatment (single daily dose on five consecutive days) of (1)
155	placebo (PLC; n = 46, M \pm SD, 22.46 \pm 2.3 years), (2) oxytocin (OT ₅ ; n = 49, M \pm SD,
156	21.78 \pm 2.3 years), or interleaved OT and PLC (OT on days 1, 3, 5, PLC on days 2, 4;
157	OT ₃ ; n = 43, M ±SD, 21.02 ±2.0 years) (see SI). To ensure compliance all subjects
158	were supervised during self-administration of all nasal sprays. Groups did not differ
159	on a number of potential confounders (see SI and Table S4). The study was approved
160	by the local ethics committee (Institutional Review Board, University of Electronic
161	Science and Technology of China) and subjects provided written informed consent.
162	The study was in accordance with the latest revision of the Declaration of Helsinki,
163	pre-registered at Clinical Trials.gov (NCT03610919 -
164	https://clinicaltrials.gov/ct2/show/NCT03610919) and in line with recommendations
165	for trials in psychological experiments (Guidi et al., 2018) (see Fig. S1 for Consort
166	flow diagram). Subjects received 500 RMB monetary compensation for participation.

- 167 **Experimental procedures**
- 168 The study employed a double-blind, randomized, placebo-controlled, between-subject
- design. The OT and PLC sprays used in the 3 groups were supplied by Sichuan Meike

170	Pharmaceutical Co. Ltd, Sichuan, China in identical dispenser bottles containing
171	identical ingredients (glycerine and sodium chloride) other than OT. In line with
172	recommended guidelines experiments started 45 minutes after intranasal
173	administration (Guastella et al., 2013). Recent studies have confirmed that intranasal
174	OT enters the brain (Lee et al 2018), increases cerebrospinal fluid and blood
175	concentrations (Striepens et al., 2013) and produces activity changes in brain regions
176	expressing OXTRs in humans at around 45 minutes after administration (Paloyelis et
177	al., 2016; Quintana et al 2019). In post-treatment interviews on days 1 and 5 subjects
178	could not identify better than chance whether they had received OT or PLC ($\chi^2 < 0.1$,
179	ps > 0.2, Table S4). For OXTR genotyping subjects provided buccal swaps on the 1^{st}
180	day for analysis of OXTR rs2254298, rs53576 SNPs (see SI and (Montag et al.,
181	2017)).

182 For the implicit face-emotion processing task 208 grayscale facial stimuli

displaying happy, neutral, angry or fearful facial expressions (n = 26 per category,

184 50% female) were used (two different stimulus sets - see **SI** for details).

185 **Primary outcomes and analysis plan**

186 Face emotion-related amygdala responses were assessed using the event-related

187 implicit face processing fMRI paradigm on treatment days 1 and 5. Intrinsic amygdala

188 connectivity was assessed by means of resting state fMRI assessments before the

task-paradigm. Valence, arousal and intensity ratings (scale: 1-9) for the facial stimuli

190 were collected immediately after MRI acquisition as additional behavioral outcomes

191	(further details see SI). In line with the main aim of the study changes in amygdala
192	face emotion reactivity and amygdala intrinsic connectivity between the 1^{st} and 5^{th}
193	day served as primary outcome measures. Changes in valence, arousal and intensity
194	ratings for the different face emotions represented an associated behavioral outcome
195	measure.

196 Imaging acquisition and analysis

- 197 Blood oxygenation level-dependent contrast functional images were acquired using
- standard sequences on a 3T GE MR750 system. High resolution T1-weighted
- 199 structural MRI data were acquired on both 1st and 5th days to improve normalization.
- 200 MRI data was preprocessed using validated procedures in SPM12 (Friston et al., 1994)
- 201 (Statistical Parametric Mapping; http://www.fil.ion.ucl.ac.uk/spm) and Data
- 202 Processing Assistant or Resting-State fMRI (Yan, 2010) (DPARSFA;
- 203 <u>http://rfmri.org/DPARSF</u>) (for details see SI). First level General Linear Models
- 204 (GLM) for the task-related fMRI data included separate regressors for the four
- 205 emotional conditions, gender identity rating period and 6 movement parameters and
- appropriate contrasts were subjected to a second level random effects analysis.

207 Primary outcomes: The effects of OT on amygdala and behavioral face emotion

- 208 reactivity and intrinsic connectivity
- 209 Differences in amygdala and behavioral responses to face emotions were examined
- using mixed ANOVAs with treatment group (PLC, OT_3 , OT_5) as between-subject and
- time point (1^{st} and 5^{th} days) and face emotion (angry, fear, happy and neutral) as

212	within-subject factors. Dependent variables were extracted target region amygdala
213	responses using the template of left and right amygdala masks from the Brainnetome
214	atlas (Fan et al., 2016) to faces (parameter estimates extracted using Marsbar,
215	http://marsbar.sourceforge.net) and valence, intensity and arousal ratings. Post-hoc
216	comparisons explored significant interactions for amygdala and behavioral ratings.
217	Associations between amygdala responses and behavioral ratings were assessed using
218	Pearson correlation.
219	Differences in resting state amygdala functional connectivity were determined
220	using a voxel-wise seed-to-whole-brain ANOVA as implemented in the SPM flexible
221	factorial design with treatment (PLC, OT ₃ , OT ₅) as between-subject and time point
222	$(1^{st} and 5^{th} days)$ as within-subject factors and amygdala connectivity maps as
223	dependent variable. (See data analysis flow chart in SI)
224	Secondary outcome measures: influence of OXTR genotype
225	For rs2254298 subjects were divided into A carriers (AA and AG) and A non-carriers
	For rs2254298 subjects were divided into A carriers (AA and AG) and A non-carriers (GG) and rs53576 into G carriers (GG and GA) and G non-carriers (AA). To explore
225	
225 226	(GG) and rs53576 into G carriers (GG and GA) and G non-carriers (AA). To explore
225 226 227	(GG) and rs53576 into G carriers (GG and GA) and G non-carriers (AA). To explore effects of genotype as a secondary outcome measure, OXTR group was included as an
225 226 227 228	(GG) and rs53576 into G carriers (GG and GA) and G non-carriers (AA). To explore effects of genotype as a secondary outcome measure, OXTR group was included as an additional between-subject factor in the corresponding ANOVAs and amygdala

232 To control for potential confounding effects of single- and repeated

OT-administration on brain structure, a voxel-based morphometry (VBM) analysis
was conducted on the T1-weighted images acquired on both testing days using
SPM12 standard procedures (Ashburner, 2007; Ashburner and Friston, 2005)(see SI).

236

Thresholding and statistical implementation

In line with our regional hypothesis the analysis of the implicit emotional face task 237 focused on the amygdala. To account for the complex design of the trial we employed 238 two analytic approaches: (1) A region of interest analysis (ROI) on the extracted beta 239 estimates from atlas-based masks for the left and right amygdala (Brainnetome Atlas, 240 Fan et al., 2016) respectively. To this end the extracted estimates were subjected to 241 242 three-way ANOVAs (treatment xtime point xface emotion) examining effects on the left and right amygdala separately. The p-value for the analysis was adopted to 243 p<0.025 (Bonferroni corrected multiple comparison 0.05/2). (2) To facilitate a more 244 specific localization of the effects and to determine a more specific seed mask for the 245 seed-to-whole brain resting state functional connectivity analysis a voxel-wise small 246 volume corrected (SVC) analysis for the entire bilateral amygdala was additionally 247 248 employed. To this end a peak-level Family-wise error (FWE) small volume correction was applied to a single mask encompassing the bilateral amygdala as provided in the 249 Brainnetome Atlas (Fan et al., 2016) (total volume of the mask, 4572.27mm³) (FWE p 250 < .05). For the seed-to-whole brain resting state data analysis a whole-brain 251 252 cluster-based FWE-correction with an initial cluster forming threshold of p < .001 and

253	FWE p < .05 was employed. Behavioral and neural (extracted parameter estimates)
254	indices were further analyzed using SPSS 22.0 with appropriate ANOVA models and
255	Bonferroni corrected post-hoc tests. $P < 0.05$ two-tailed was considered significant.
256	Partial eta squared (η^2_p) and Cohen's <i>d</i> were computed for behavioral results as
257	measures of effect size and SPSS outlier analysis was used to confirm the absence of
258	statistical outliers. Full details of the post-hoc and correlation analyses are provided in
259	the SI (Tables $S7 - S11$).

260 **Results**

261 Primary outcome measure: ROI analysis of acute and repeated doses on

262 **OT-evoked changes in amygdala responses to face emotions**

263	Examination of the extracted parameter estimates from the amygdala (a priori ROI
264	approach in accordance with trial pre-registration) revealed a significant three-way
265	ANOVA for the right amygdala ($F_{(6,405)}=2.563$; p<0.019), but not the left amygdala
266	$(F_{(6,405)}=1.860; p=0.087)$. Post-hoc analyses on the extracted beta values from the
267	right amygdala mask on the 1 st day revealed that both OT groups compared to PLC
268	exhibited a suppression of right amygdala reactivity (fear: ps < 0.015, angry: ps <
269	0.016; happy: $ps < 0.041$: neutral: $ps < 0.017$). Analysis on the 5 th day revealed that
270	the OT_3 group exhibited a suppression of right amygdala reactivity to fear and angry
271	faces relative to both the PLC (fear: $p = 0.003$, angry: $p = 0.008$) and OT_5 groups (fear:
272	p = 0.021; angry: $p = 0.082$) but the OT ₅ group did not (ps > 0.315, relative to PLC
273	group). The OT ₃ group also exhibited reduced right amygdala reactivity to happy

274	faces on the 5 th day compared with the PLC group ($p = 0.028$) but there was no
275	significant difference between OT_3 and OT_5 groups (p = 0.272). There were no
276	significant effects of OT on the 5^{th} day for neutral faces (ps>0.203, although OT ₃ vs
277	PLC was marginal, $p = 0.052$). While amygdala reactivity to fear faces did not differ
278	in the PLC group between days 1 and 5 ($p = 0.356$), its reduction in the OT ₃ group on
279	day 5 was equivalent to day 1 ($p = 0.538$) whereas in the OT ₅ group the reduction on
280	day 5 was significantly less than on day 1 ($p = 0.035$). Amygdala reactivity to angry
281	faces decreased significantly more in the OT_3 group on day 5 relative to day 1 (p =
282	0.006), although it also did so in the PLC group for both angry ($p = 0.007$) and neutral
283	(p = 0.028) (Fig. 1b-e).

284 Primary outcome measure: behavioral rating analysis of acute and

285 repeated doses to face emotions

- 286 Mixed ANOVAs on the behavioral data revealed a significant main effect of
- treatment group on arousal ratings (arousal: $F_{2, 135} = 5.06$, p = 0.008, $\eta^2_p = 0.07$) due to
- ratings generally being lower in the OT_3 group. There was also a marginal significant
- treatment group x time point x face emotion interaction effect for arousal ($F_{6,405}$ =

290 1.83, p = 0.093, $\eta_{p}^{2} = 0.03$) and a significant one for intensity (F_{6,405} = 3.327, p =

- 291 0.004, $\eta_p^2 = 0.05$). Post-hoc analysis showed that intensity ratings were significantly
- reduced for fear faces in the OT₃ group on the 5th day (fear: p = 0.004 versus PLC, d =

293 0.62, 95% CI, -1.299 to -0.247, p = 0.088 versus OT₅, d = 0.33, 95% CI, -0.968 to

294 0.068). Exploratory post-hoc analysis of arousal ratings revealed a similar reduction

295	to fear faces on day 5 (p = 0.001 versus PLC, $d = 0.77$, 95% CI, -1.544 to -0.420, p =
296	0.033 versus OT ₅ , $d = 0.42$, 95% CI, -1.158 to -0.051). Arousal ratings to fear faces
297	were also decreased in the OT_3 group on the 1^{st} day compared to the PLC group but
298	not the OT ₅ group (arousal: $p = 0.015$ versus PLC, $d = 0.60, 95\%$ CI, 0.129 to 1.175,
299	p = 0.355 versus OT ₅ , 95% CI, -0.268 to 0.744). Arousal and intensity ratings to
300	angry faces were reduced on day 5 compared with day 1 in the OT_3 (arousal: p =
301	0.001, <i>d</i> = 0.30, 95% CI, 0.164 to 0.619, intensity: p = 0.001, <i>d</i> = 0.32, 95% CI, 0.173
302	to 0.641) and OT ₅ groups (arousal: $p = 0.023$, $d = 0.19$, 95% CI, 0.032 to 0.461,
303	intensity: $p = 0.006$, $d = 0.26$, 95% CI, 0.088 to 0.526). There were no significant
304	differences for angry, neutral and happy faces between OT and PLC groups on the 1st
305	day (ps >0.194, although OT ₅ vs PLC was marginal, p=0.051 for neutral faces) and 5^{th}
306	day (ps >0.671, although OT_3 vs PLC p=0.053 was marginal for angry faces). There
307	was however a significant group difference between OT_3 and OT_5 on the 1 st and 5 th
308	day for happy and neutral faces (ps<0.007) (Fig.2). While there was a significant
309	3-way interaction for valence ratings (F _{6, 405} = 2.63, p = 0.016, η^2_{p} = 0.04), post-hoc
310	analysis revealed no significant differences between OT and PLC groups on the 1st
311	(ps > 0.200) or 5 th days $(ps > 0.173)$.

313 effects of acute or repeated doses of OT on gray matter volumes.

Associations between amygdala responses and behavioral ratings to emotional faces

316	Associations between right amygdala activation (extracted parameter estimates from
317	the right amygdala mask as provided by the Brainnetome atlas) and emotional arousal
318	and intensity scores to fear faces were observed in the PLC group on the 1 st day
319	(arousal: $r = 0.295$, $p = 0.023$; intensity: $r = 0.455$, $p = 0.001$) demonstrating that
320	greater amygdala activation in response to fear faces was associated with increased
321	anxiety. This association was absent in both OT groups on the 1^{st} day (arousal: OT ₃ , r
322	= 0.041, p = 0.398; OT ₅ , r = 0.050, p = 0.366; intensity: OT ₃ , r = 0.098, p = 0.265;
323	OT ₅ , $r = 0.164$, $p = 0.130$). A similar trend occurred on the 5 th day (arousal: PLC, $r =$
324	0.306, $p = 0.019$; OT_3 , $r = -0.011$, $p = 0.471$; OT_5 group, $r = -0.120$, $p = 0.206$;
325	intensity: PLC, r = 0.212, p = 0.079; OT ₃ , r = -0.108, p = 0.246; OT ₅ group, r =-0.043,
326	p = 0.385) (Fig.3). There was a similar relationship with responses to angry faces for
327	intensity but not arousal ratings in the PLC group on the 1^{st} day. (arousal: $r = 0.107$, p
328	= 0.240; intensity: $r = 0.297$, $p = 0.023$). No associations were found for responses to
329	neutral or happy faces.
220	

Primary outcome measure: effects of acute and repeated oxytocin doses on

331 resting-state functional connectivity

To facilitate a more precise localization of the coordinates of amygdala for the resting state analysis a voxel-wise mixed ANOVA with treatment group (PLC, OT_3 , OT_5) as between-subject, time point (1st and 5th days) and face emotion (happy, neutral, angry and fear) as within-subject factor was computed on the task-based data. This analysis revealed a significant three-way interaction effect in the right amygdala after small

337	volume correction for the bilateral mask encompassing the entire amygdala ($k = 7$,
338	p _{FWE} = 0.021, F _{6,405} =4.47, peak MNI co-ordinate: x=18, y=-7, z=-16) (Fig.4a)
339	confirming the findings from the ROI analysis which revealed a significant interaction
340	effect for the right amygdala only. An amygdala seed-to-whole brain fMRI
341	resting-state analysis employing this region as seed (6 radius sphere centered at $x=18$,
342	y=-7, z=-16) by mixed-effect ANOVA revealed a main effect of treatment (OT ₃ , OT ₅
343	and PLC) on amygdala functional coupling with the anterior prefrontal cortex (peak
344	MNI coordinate x = -3, y =53, z = -19, $F_{2, 135} = 16.55$, $p_{FWE} = 0.001$, k = 88) (see Fig.
345	4a) but no treatment group x time point interaction. Right amygdala intrinsic
346	connectivity with the prefrontal cortex was stronger in both the OT_3 (k = 74, p_{FWE} =
347	0.014, $x = -3$, $y = 53$, $z = -19$) and OT ₅ groups ($k = 127$, $p_{FWE} = 0.001$, $x = -3$, $y = 53$,
348	z = -19) relative to PLC. The OT ₃ and OT ₅ groups did not differ significantly on the
349	1^{st} (p = 0.147) or 5^{th} (p = 0.107) days (see Fig. 4b). Correlation analysis revealed no
350	significant association between resting state and amygdala task-related changes
351	(r=-0.08, p=0.59 in PLC group) or behavioral ratings of emotional faces
352	(-0.085 <rs<0.055, ps=""> 0.57).</rs<0.055,>
353	Secondary outcome measure: Associations between OT-effects and OXTR
354	genotype

355 The number of G-carriers and G-non-carriers of rs53576 and A-carriers and

A-non-carriers of rs2254298 did not differ between the three groups and both SNPs

357 satisfied Hardy Weinberg Equilibrium (see **Tables S2 and S3**). A four-way mixed

358	ANOVA with treatment group and genotype as between- and time point and face
359	emotion as within-subject factors revealed significant treatment x genotype
360	interactions for both rs2254298 and rs53576 (rs 2254298: $F_{2, 105} = 3.17$, p = 0.046,
361	rs53576: $F_{2, 105} = 3.23$, p = 0.044) for amygdala responses to emotional faces,
362	although they would not survive a Bonferroni correction for 4 genotypes (i.e.
363	p<0.0125). Post-hoc analysis showed that reduced amygdala reactivity to emotional
364	faces in both OT groups occurred in A-carriers of rs2254298 (ps < 0.009) but not
365	A-non-carriers (ps>0.587) and G-non-carriers of rs 53576 (ps < 0.002) but not
366	G-carriers (ps>0.196) (see Fig. 5a-b). For behavioral ratings there were significant
367	treatment group x genotype interactions for both arousal and intensity ratings for
368	rs2254298 (arousal: F _{2, 105} = 6.60, p = 0.002, η^2_{p} = 0.11; intensity: F _{2, 105} = 3.85, p =
369	0.024, $\eta^2_{p} = 0.07$). Post-hoc analysis showed that decreased ratings for faces in the
370	OT_3 group only occurred in A-carriers (arousal: versus PLC: p = 0.002, d = 4.68, 95%)
371	CI, 0.363 to 1.524 and OT ₅ p < 0.001, $d = 6.56$, 95% CI, 0.743 to 1.904; intensity:
372	PLC: p = 0.021, d = 3.40, 95% CI, 0.109 to 1.301; OT ₅ : p = 0.003, d = 4.40, 95% CI,
373	0.314 to 1.507). No significant main or interaction effects involving treatment and
374	genotype were found for resting state functional connectivity between amygdala and
375	prefrontal cortex (rs 2254298 all ps > 0.123; rs53576 all ps > 0.566).

376 **Discussion**

377 Overall, our findings validate OT-reductions in amygdala responses to face emotions

and associated emotional intensity and arousal ratings for fear faces, together with

379	increased resting state functional connectivity between the amygdala and prefrontal
380	cortex as robust markers for its putative therapeutic mechanisms of action. While,
381	these task-dependent and resting-state effects of OT show a different sensitivity to
382	repeated intranasal doses and OXTR genotype our findings indicate that to achieve
383	maximal effects of chronic treatment on neural and behavioral responses to face
384	emotion stimuli and resting-state changes the optimal protocol may be to administer
385	24IU doses every other day rather than daily.
386	Our findings are highly consistent with preclinical animal models demonstrating
387	OXTR desensitization following repeated doses of OT in some brain regions (Terenzi
388	and Ingram, 2005; Smith et al., 2005; Stoop, 2012) and that chronic administration
389	can reduce brain OXTR expression (Du et al., 2017) and alter patterns of
390	neurochemical release (Benner et al., 2018). Importantly, chronic doses of OT in
391	rodents fail to produce anxiolytic effects normally seen with single doses (Du et al.,
392	2017) which mirrors our present observations. The apparent long-lasting
393	desensitization effects of daily OT administration on amygdala responses to
394	threatening and happy faces may be contributed to by dose magnitude and so possibly
395	lower daily doses might be less problematic. We also observed some evidence for
396	reduced amygdala and behavioral responses to repeated emotional face presentations
397	in the PLC group in line with previous observations (Fischer et al., 2003; Wright et al.,
398	2001), even though different sets of face stimuli were used at the two time-points.
399	This may have served to reduce time-dependent effects of OT to some extent.

400	The amygdala is one of the main neural substrates mediating OT's functional
401	effects and its attenuation of reactivity to threatening stimuli is considered as a
402	putative primary therapeutic mechanism of action (see Jurek and Neumann, 2018;
403	Kendrick et al., 2017; Neumann and Slattery, 2016). However, in the current study we
404	demonstrated similar effects of OT in reducing right amygdala responses to all
405	emotional faces, although desensitization effects were only significant for threatening
406	(fear and anger) and happy faces. While some previous studies have found effects of
407	OT only for fear faces (Spengler et al., 2017) or for fear and angry ones (Kirsch et al.,
408	2005), our current findings are in agreement with a number of others reporting that it
409	can reduce amygdala responses to both positive and negative (Domes et al., 2007) or
410	all face emotions (Koch et al., 2016; Quintana et al., 2016). A possible explanation for
411	these differences could be that studies, including our own, using presentation
412	strategies where subjects are not directly required to identify or discriminate between
413	face emotions (Domes et al., 2007; Koch et al., 2016; Quintana et al., 2016) have
414	tended to report valence-independent results. Importantly however, only the
415	magnitude of amygdala responses to fear faces was positively associated with arousal
416	and intensity ratings in the PLC group and OT exerted an anxiolytic action by both
417	reducing these ratings and abolishing their correlation with amygdala activation.
418	Dysregulations in amygdala and behavioral responses to threatening stimuli have been
419	observed across major psychiatric disorders, particularly those characterized by
420	marked social impairments and anxiety (Hennessey et al., 2018; Neumann and
421	Slattery, 2016). There was some evidence that behavioral anxiolytic effects of OT

were greater after repeated compared to single doses in the group receiving OT every
other day for angry faces but not in terms of amygdala responses. Possibly the short 5
day period for OT-treatment was not sufficient to demonstrate robust enhancement
effects of repeated doses and time-dependent enhancement effects of longer duration
treatment need to be investigated in studies on clinical populations.

A major finding from our secondary outcome measure is that OT's attenuations 427 of neural and behavioral responses to face emotions are highly dependent on OXTR 428 genotype. Only G non-carriers of rs53576 and A-carriers of rs2254298 showed 429 significant reductions in amygdala responses to face emotions under OT although 430 only A-carriers of rs2254298 showed evidence for significant reductions in arousal 431 and intensity ratings. A-carriers of both SNPs have frequently been associated with 432 social dysfunction in autism and social anxiety disorders (Cataldo et al., 2018; Jurek 433 and Neumann, 2018). A recent haplotype-based analysis of OXTR SNPs including 434 rs53576 and rs2254298 also indicated an association with sensitivity to OT-effects on 435 436 face recognition (Chen et al., 2015).

Interestingly, task-related and intrinsic network changes produced by OT showed
a strikingly different sensitivity to repeated doses and OXTR genotype and there were
no associations between resting state connectivity and either amygdala or behavioral
responses to face emotions. However, for the resting state effects of OT there was no
advantage of giving OT daily as opposed to every other day. Intrinsic networks may
therefore be less sensitive to the effects of repeated OT administration or OXTR

genotype than those engaged by external social emotional stimuli, although arguably
the effects of OT on neural processing during actual processing of social cues should
be of greatest therapeutic relevance.

There are several limitations in the current study. Firstly, we only included male 446 subjects to increase relevance to potential therapeutic use in autism and to avoid 447 menstrual cycle effects. There is however increasing evidence for sex-dependent 448 effects of OT, notably for amygdala responses (Gao et al., 2016; Jurek and Neumann, 449 2018; Lieberz et al., 2019; Luo et al., 2017) and also for rs53576 (Feng et al., 2015). 450 451 Thus, females may show different responses to repeated doses of OT and associations with receptor genotype. Secondly, for the genotype analysis, subject numbers are 452 relatively low for establishing robust associations. While treatment x genotype 453 interactions only passed Bonferroni correction for arousal ratings, post-hoc tests for 454 both behavioral and amygdala effects were highly significant. . The AA allele of 455 rs53576 also occurs more frequently in Asian and Caucasian populations (Butovskaya 456 457 et al., 2016). Finally, we only examined the effects of one dose and time course for the effects of OT and there may be dose-dependent and temporal variations. The 24IU 458 dose and 45 min post-treatment time course used are the same as in many previous 459 studies demonstrating both task and resting-state effects of OT (Kendrick et al., 2017) 460 and maximal effects on reduced amygdala responses to fear faces occur with a 24IU 461 dose from 45-75 min (Spengler et al., 2017). However, higher doses may produce 462 different effects (Spengler et al., 2017) and a recent regional cerebral blood flow 463

464 study has reported reduced resting amygdala activity at shorter time points following465 40IU intranasal OT (Martins et al., 2020).

466	In conclusion, the current study provides the first evidence for an important
467	influence of OT dose frequency and receptor genotype on its modulation of neural
468	and behavioral responses to emotional faces in healthy human subjects. Dose
469	frequency therefore requires further empirical evaluation in patient populations given
470	that it can critically determine treatment efficacy in clinical trials employing chronic
471	administration.
472	Acknowledgement: We thank the reviewers and editor for their comments and
473	suggestions for improving the manuscript. Funding: This project was supported by
474	National Natural Science Foundation of China (NSFC) grant numbers 31530032
475	(KMK) and 91632117 (BB). Author contributions: JK and KMK designed the
476	experiment. JK, YZ and CS carried out the experiment. JK, KMK, CM, FZ and BB
477	analyzed the experiment and JK, KMK, CM and BB wrote the paper. All authors
478	contributed to the conception of the study and approved the paper. Competing
479	interests: The authors declare that they have no competing interests.

484 **References**

485	Bales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing,
486	G. M., & Mendoza, S. P. (2013). Chronic intranasal oxytocin causes
487	long-term impairments in partner preference formation in male prairie voles.
488	Biological Psychiatry, 74(3), 180-188.
489	Benner, S., Aoki, Y., Watanabe, T., Endo, N., Abe, O., Kuroda, M., & Kasai, K.
490	(2018). Neurochemical evidence for differential effects of acute and repeated
491	oxytocin administration. Molecular Psychiatry, 1-11.
492	Brüne, M. (2012). Does the oxytocin receptor polymorphism (rs2254298) confer
493	'vulnerability' for psychopathology or 'differential susceptibility'? Insights
494	from evolution. BMC Medicine, 10(1), 38.
495	Butovskaya, P. R., Lazebny, O. E., Sukhodolskaya, E. M., Vasiliev, V. A., Dronova,
496	D. A., Fedenok, J. N., & Butovskaya, M. L. (2016). Polymorphisms of two
497	loci at the oxytocin receptor gene in populations of Africa, Asia and South
498	Europe. BMC Genetics, 17(1), 17.
499	Cataldo, I., Azhari, A., & Esposito, G. (2018). A review of oxytocin and
500	arginine-vasopressin receptors and their modulation of autism spectrum
501	disorder. Frontiers in Molecular Neuroscience, 11, 27.
502	Chen, F. S., Kumsta, R., Dvorak, F., Domes, G., Yim, O. S., Ebstein, R. P., &
503	Heinrichs, M. (2015). Genetic modulation of oxytocin sensitivity: a
504	pharmacogenetic approach. Translational Psychiatry, 5(10), e664-e664.

505	Cremers, H. R., Wager, T. D., & Yarkoni, T. (2017). The relation between statistical
506	power and inference in fMRI. <i>PloS one</i> , 12(11), e0184923.

- 507 Domes, G., Heinrichs, M., Gläscher, J., Büchel, C., Braus, D. F., & Herpertz, S. C.
- 508 (2007). Oxytocin attenuates amygdala responses to emotional faces regardless

509 of valence. *Biological Psychiatry*, 62(10), 1187-1190.

- 510 Du, P., He, Z., Cai, Z., Hao, X., Dong, N., Yuan, W., ... & Tai, F. (2017). Chronic
- 511 central oxytocin infusion impairs sociability in mandarin voles. *Pharmacology*512 *Biochemistry and Behavior*, 161, 38-46.
- 513 Eckstein, M., Becker, B., Scheele, D., Scholz, C., Preckel, K., Schlaepfer, T. E., ... &
- Hurlemann, R. (2015). Oxytocin facilitates the extinction of conditioned fear
 in humans. *Biological Psychiatry*, 78(3), 194-202.
- 516 Eckstein, M., Markett, S., Kendrick, K. M., Ditzen, B., Liu, F., Hurlemann, R., &
- 517 Becker, B. (2017). Oxytocin differentially alters resting state functional
- 518 connectivity between amygdala subregions and emotional control networks:
- 519 Inverse correlation with depressive traits. *Neuroimage*, 149, 458-467.
- 520 Eklund, A., Nichols, T. E., & Knutsson, H. (2016). Cluster failure: Why fMRI
- 521 inferences for spatial extent have inflated false-positive rates. *Proceedings of*
- *the National Academy of Sciences*, 113(28), 7900-7905.
- 523 Fan, L., Li, H., Zhuo, J., Zhang, Y., Wang, J., Chen, L., ... & Fox, P. T. (2016). The
- 524 human brainnetome atlas: a new brain atlas based on connectional architecture.
- 525 *Cerebral Cortex*, 26(8), 3508-3526.

526	Feng (Γ	Lori	Α	Waldman	ΙD	Binder	ΕB	Haroon	E	& Rilling,	ΙK	(2015)
520	r ung, v	C., .	LUII,	11.,	waluman,	\mathbf{I}	, Dinuci,	L. D.,	, maroon,	L.,	a Rinnig,	J. IX.	(2013).

- 527 A common oxytocin receptor gene (OXTR) polymorphism modulates
- 528 intranasal oxytocin effects on the neural response to social cooperation in
- humans. *Genes, Brain and Behavior*, 14(7), 516-525.
- 530 Fischer, H., Wright, C.I., Whalen, P.J., McInerney, S.C., Shine, L.M., & Rauch, S.L.
- 531 (2003). Brain habituation during repeated exposure to fearful and neutral faces.
 532 *Brain Research Bulletin* 59(5), 387-392.
- 533 Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. P., Frith, C. D., & Frackowiak,
- R. S. (1994). Statistical parametric maps in functional imaging: a general
 linear approach. *Human Brain Mapping*, 2(4), 189-210.
- 536 Gao, S., Becker, B., Luo, L., Geng, Y., Zhao, W., Yin, Y., ... & Kendrick, K.M.
- 537 (2016). Oxytocin, the peptide that bonds the sexes also divides them.
- 538 *Proceedings of the National Academy of Sciences*, 113(27), 7650-7654.
- 539 Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I.
- 540 B., ... & Einfeld, S. L. (2015). The effects of a course of intranasal oxytocin on
- 541 social behaviors in youth diagnosed with autism spectrum disorders: a
- 542 randomized controlled trial. *Journal of Child Psychology and Psychiatry*, 56(4),
- **543 444-452**.
- 544 Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger,
- 545 H. M., ... & Banati, R. B. (2013). Recommendations for the standardisation of
- 546 oxytocin nasal administration and guidelines for its reporting in human
- 547 research. *Psychoneuroendocrinology*, 38(5), 612-625.

548	Guidi I	Brakemeier	E L	Bockting	CL	Cosci F	Cuiiners	Р	Iarrett	RR	
540	Oului, J.,	DIAKCHICICI	, L'. L.	, DUCKIIII ,	U. L.,	COSCI, I'.,	Curpers	, I ., .	Januti,	Г. D. ,	,

- 549 & Rief, W. (2018). Methodological recommendations for trials of
- 550 psychological interventions. *Psychotherapy and Psychosomatics*, 87(5),
- 551 276-284.
- Halverson, T., Jarskog, L. F., Pedersen, C., & Penn, D. (2019). Effects of oxytocin on
- empathy, introspective accuracy, and social symptoms in schizophrenia: A
- 554 12-week twice-daily randomized controlled trial. *Schizophrenia Research*, 204,
- 555 178-182.
- 556 Hennessey, T., Andari, E., & Rainnie, D. G. (2018). RDoC-based categorization of
- amygdala functions and its implications in autism. *Neuroscience & Biobehavioral Reviews*, 90, 115-129.
- 559 Huang, H., Michetti, C., Busnelli, M., Manago, F., Sannino, S., Scheggia, D., ... &
- 560 Scattoni, M. L. (2014). Chronic and acute intranasal oxytocin produce
- 561 divergent social effects in mice. *Neuropsychopharmacology*, 39(5),
- 562 1102-1114.
- Jarskog, L. F., Pedersen, C. A., Johnson, J. L., Hamer, R. M., Rau, S. W., Elliott, T.,
- 564 & Penn, D. L. (2017). A 12-week randomized controlled trial of twice-daily
- intranasal oxytocin for social cognitive deficits in people with schizophrenia. *Schizophrenia Research*, 185, 88-95.
- Jurek, B., & Neumann, I. D. (2018). The oxytocin receptor: from intracellular
 signaling to behavior. *Physiological Reviews*, 98(3), 1805-1908.

- Kendrick, K. M., Guastella, A. J., & Becker, B. (2017). Overview of human oxytocin 569
- research. In Behavioral Pharmacology of Neuropeptides: Oxytocin (pp. 570
- 321-348). Springer, Cham. pp. 321-348. 571
- Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., ... & 572
- 573 Meyer-Lindenberg, A. (2005). Oxytocin modulates neural circuitry for social
- cognition and fear in humans. Journal of Neuroscience, 25(49), 11489-11493. 574
- Koch, S.B.J., van Zuiden, M., Nawijn, L., Frijling, J.L., Veltman, D.J. (2016). 575
- Intranasal oxytocin administration dampens amygdala reactivity towards 576
- 577 emotional faces in male and female PTSD patients.
- Neuropsychopharmacology, 41, 1495-1504. 578

- Lieberz, J., Scheele, D., Spengler, F. B., Matheisen, T., Schneider, L., Stoffel-Wagner, 579
- B., ... & Hurlemann, R. (2019). Kinetics of oxytocin effects on amygdala and striatal reactivity vary between women and men. *Neuropsychopharmacology*, 581 1-7. 582
- Lee, M. R., Scheidweiler, K. B., Diao, X. X., Akhlaghi, F., Cummins, A., Huestis, M. 583
- A., ... & Averbeck, B. B. (2018). Oxytocin by intranasal and intravenous 584
- routes reaches the cerebrospinal fluid in rhesus macaques: determination using 585 a novel oxytocin assay. *Molecular Psychiatry*, 23(1), 115-122. 586
- Lohse, M. J., & Hofmann, K. P. (2015). Spatial and Temporal Aspects of Signaling 587
- by G-Protein–Coupled Receptors. Molecular Pharmacology, 88(3), 572-578. 588

589	Luo, L., Becker, B., Geng, Y., Zhao, Z., Gao, S., Zhao, W., & Hu, J. (2017).
590	Sex-dependent neural effect of oxytocin during subliminal processing of
591	negative emotion faces. Neuroimage, 162, 127-137.
592	Martins, D.A., Mazibuko, N, Zelaya, F., Vasilakopoulou, S., Loveridge, J., Oates,
593	U., & Paloyelis, Y. (2020). Effects of route of administration on
594	oxytocin-induced changes in regional cerebral blood flow in humans. Nature
595	Communications doi: 10.1038/s41467-020-14845-5
596	Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011). Oxytocin and
597	vasopressin in the human brain: social neuropeptides for translational
598	medicine. Nature Reviews Neuroscience, 12(9), 524-538.
599	Montag, C., Sindermann, C., Melchers, M., Jung, S., Luo, R., Becker, B., &
600	Kendrick, K. M. (2017). A functional polymorphism of the OXTR gene is
601	associated with autistic traits in Caucasian and Asian populations. American
602	Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 174(8),
603	808-816.
604	Mueller, K., Lepsien, J., Möller, H. E., & Lohmann, G. (2017). Commentary: Cluster
605	failure: Why fMRI inferences for spatial extent have inflated false-positive
606	rates. Frontiers in Human Neuroscience, 11, 345.
607	Neumann, I. D., & Slattery, D. A. (2016). Oxytocin in general anxiety and social fear:
608	a translational approach. Biological Psychiatry, 79(3), 213-221.


609	Paloyelis, Y., Doyle, O. M., Zelaya, F. O., Maltezos, S., Williams, S. C., Fotopoulou,
610	A., & Howard, M. A. (2016). A spatiotemporal profile of in vivo cerebral
611	blood flow changes following intranasal oxytocin in humans. Biological
612	Psychiatry, 79(8), 693-705.
613	Parker, K. J., Garner, J. P., Libove, R. A., Hyde, S. A., Hornbeak, K. B., Carson, D.
614	S., & Hardan, A. Y. (2014). Plasma oxytocin concentrations and OXTR
615	polymorphisms predict social impairments in children with and without autism
616	spectrum disorder. Proceedings of the National Academy of Sciences, 111(33),
617	12258-12263.
618	Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). Seven-transmembrane
619	receptors. Nature Reviews Molecular Cell Biology, 3(9), 639-650.
620	Poldrack, R. A., Baker, C. I., Durnez, J., Gorgolewski, K. J., Matthews, P. M.,
621	Munafò, M. R., & Yarkoni, T. (2017). Scanning the horizon: towards
622	transparent and reproducible neuroimaging research. Nature Reviews
623	Neuroscience, 18(2), 115.
624	Quintana, D. S., Rokicki, J., van der Meer, D., Alnæs, D., Kaufmann, T.,
625	C órdova-Palomera, A., & Westlye, L. T. (2019). Oxytocin pathway gene
626	networks in the human brain. Nature Communications, 10(1), 1-12.
627	Quintana, D.S., Westlye, L.T., Alnaes, D., Rustan, Ø.G., Kaufmann, T.,&
628	Andreassen, O.A. (2016). Low dose intranasal oxytocin delivered with Breath
629	Powered device dampens anygdala response to emotional stimuli: A

630	peripheral effect-controlled within-subjects randomized dose-response fMRI
631	trial. Psychoneuroendocrinology, 69, 180-188.
632	Russell, J. A. (2018). 50 years of advances in neuroendocrinology. Brain and
633	Neuroscience Advances, 2, 1-20.
634	Smith, M. P., Ayad, V. J., Mundell, S. J., McArdle, C. A., Kelly, E., & López Bernal,
635	A. (2006). Internalization and desensitization of the oxytocin receptor is
636	inhibited by Dynamin and clathrin mutants in human embryonic kidney 293
637	cells. Molecular Endocrinology, 20(2), 379-388.
638	Spengler, F. B., Schultz, J., Scheele, D., Essel, M., Maier, W., Heinrichs, M., &
639	Hurlemann, R. (2017). Kinetics and dose dependency of intranasal oxytocin
640	effects on amygdala reactivity. Biological Psychiatry, 82(12), 885-894.
641	Sripada, C. S., Phan, K. L., Labuschagne, I., Welsh, R., Nathan, P. J., & Wood, A. G.
642	(2013). Oxytocin enhances resting-state connectivity between amygdala and
643	medial frontal cortex. International Journal of Neuropsychopharmacology,
644	16(2), 255-260.
645	Stoop, R. (2012). Neuromodulation by oxytocin and vasopressin. Neuron, 76(1),
646	142-159.
647	Striepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wülner, U., Maier, W., &
648	Hurlemann, R. (2013). Elevated cerebrospinal fluid and blood concentrations
649	of oxytocin following its intranasal administration in humans. Scientific
650	<i>Reports</i> , 3, 3440.

651	Terenzi, M. G., & Ingram, C. D. (2005). Oxytocin-induced excitation of neurones in
652	the rat central and medial amygdaloid nuclei. Neuroscience, 134(1), 345-354.
653	Wang, D., Yan, X., Li, M., & Ma, Y. (2017). Neural substrates underlying the effects
654	of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies. Social
655	Cognitive and Affective Neuroscience, 12(10), 1565-1573.
656	Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., &
657	Kasai, K. (2015). Clinical and neural effects of six-week administration of
658	oxytocin on core symptoms of autism. Brain, 138(11), 3400-3412.
659	Wright, C. I., Fischer, H., Whalen, P. J., McInerney, S. C., Shin, L. M., Rauch, S. L.
660	(2001). Differential prefrontal cortex and amygdala habituation to repeatedly
661	presented emotional stimuli. Neuroreport, 12,379-383.
662	Yamasue, H., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., &
663	Yoshimura, Y. (2018). Effect of intranasal oxytocin on the core social
664	symptoms of autism spectrum disorder: a randomized clinical trial. Molecular
665	Psychiatry, 1-10.
666	Chao-Gan, Y., & Yu-Feng, Z. (2010). DPARSF: a MATLAB toolbox for "pipeline"
667	data analysis of resting-state fMRI. Frontiers in Systems Neuroscience, 4.
668	Yang, S., Dong, X., Guo, X., Han, Y., Song, H., Gao, L., & Zhang, X. (2017).
669	Serum oxytocin levels and an oxytocin receptor gene polymorphism
670	(rs2254298) indicate social deficits in children and adolescents with autism
671	spectrum disorders. Frontiers in Neuroscience, 11, 221.

- 672 Young, L. J., & Barrett, C. E. (2015). Can oxytocin treat autism? *Science*, 347(6224),
- 673825-826.
- 674 Zhang, Z., & Yuan, K.H. (2018). Practical Statistical Power Analysis Using
- 675 Webpower and R (Eds). *Granger*, IN: ISDSA Press.
- 676 Zhao, W., Becker, B., Yao, S., Ma, X., Kou, J., & Kendrick, K. M. (2019). Oxytocin
- 677 enhancement of the placebo effect may be a novel therapy for working
- 678 memory impairments. *Psychotherapy and Psychosomatics*, 88(2), 125-126.
- 679 Zhao, Z., Yao, S., Li, K., Sindermann, C., Zhou, F., Zhao, W., ... & Becker, B. (2019).
- 680 Real-time functional connectivity-informed neurofeedback of
- 681 amygdala-frontal pathways reduces anxiety. *Psychotherapy and*
- 682 *Psychosomatics*, 88(1), 5-15.
- 683

685 Figure Legends



686

Fig.1 The effect of intranasal oxytocin (OT) treatment on neural responses to faces. (a)

688 The mask of right amygdala from the Brainnetome atlas (Fan et al., 2016)(b-e) Post

689 hoc analysis on extracted parameter estimates from the right amygdala mask for all

- face emotion categories on the 1st and 5th days.# p < 0.1, * p < 0.05, ** p < 0.01,
- 691 two-tailed. Bars depict standard errors.




Fig.2 The effects of oxytocin (OT) on arousal and intensity ratings for face emotions. (a) OT decreased arousal and intensity ratings of fear faces on both the 1st and the 5th days of treatment in the group receiving OT on alternate days (OT₃) compared with placebo (PLC) and ratings were significantly reduced on day 5 relative to day 1. The group receiving OT every day (OT₅) did not show significant effects on either day 1 or 5. No effects of OT on ratings for (b) anger, (c) happy and (d) happy face emotions. # p < 0.1, * p < 0.05, ** p < 0.01 two-tailed, Bars depict standard errors.

700







Fig.3 Associations between intensity and arousal ratings of fear faces and amygdala
activation in the placebo (PLC) and two OT treatment groups (OT₃ and OT) on days 1
and 5. The magnitude of right amygdala (from the Brainnetome atlas) responses was
positively correlated with arousal and intensity ratings in the PLC group on day 1 but
not in the OT groups. There was a similar trend on day 5. *p< 0.05. **p<0.01
(Pearson Correlation).

708



710

Fig.4 The effects of oxytocin (OT) on resting state functional connectivity (a) 711 schematic visualization of the identified functional pathway between the right 712 amygdala and anterior prefrontal cortex (replicating Eckstein et al., 2017). (b) Seed to 713 whole-brain analysis of functional connectivity (FC, seed region right amygdala, 6mm 714 sphere, x=18, y=-7, z=-16) revealed significantly increased functional connectivity 715 716 between right amygdala and anterior prefrontal cortex ($p_{FWE} = 0.039$, x = -36, y = 59, z 717 = -7) in both OT treatment groups (OT₃ and OT₅) on both, days 1 and 5 relative to placebo (PLC). Line graphs depict the extracted parameter estimates from right 718 amygdala connectivity with anterior prefrontal cortex (M \pm SE). * p < 0.05, ** p < 719 0.01 two-tailed. Bars indicate standard errors. 720 721 722 723






Fig.5 Influence of oxytocin (OT) receptor genotype on the effects of intranasal OT on 726 727 right amygdala and behavioral responses to face emotions (n = 111 subjects). (a) for rs 53576 only G-non carriers (i.e. AA) showed reduced amygdala responses to faces 728 (PLC, $n_{G+}=15$, $n_{G-}=21$; OT₃, $n_{G+}=17$, $n_{G-}=24$; OT₅, $n_{G+}=20$, $n_{G-}=14$); (b) for 729 rs2254298 only A-carriers (i.e. AA and AG) in the groups with intranasal oxytocin 730 (OT) treatment showed reduced amygdala responses to faces (PLC, $n_{A+}=20$, $n_{A-}=16$; 731 OT₃, n_{A+}=23, n_A=18; OT₅, n_{A+}=20, n_A=14) ; (c) for rs2254298 only A-carriers (i.e. 732 733 AA and AG) in the groups with intranasal oxytocin (OT) treatment showed reduced emotional arousal ratings ** p < 0.01, two-tailed t-test (Bonferroni corrected 734 significance threshold of p = 0.0125). Bars indicate standard errors. 735